<?xml version="1.0" encoding="UTF-8"?>

<Composition xmlns="http://hl7.org/fhir">
  <id value="COVID19IntensiveCareTreatmentGuideline"/>
  <meta>
    <profile value="https://www.netzwerk-universitaetsmedizin.de/fhir/screen4care/StructureDefinition/guideline"/>
  </meta>
  <text>
    <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Composition</b><a name="COVID19IntensiveCareTreatmentGuideline"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Composition &quot;COVID19IntensiveCareTreatmentGuideline&quot; </p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-guideline.html">Clinical Practice Guideline</a></p></div><p><b>identifier</b>: Resource identifier: 113-001</p><p><b>version</b>: 7.0</p><p><b>status</b>: final</p><p><b>type</b>: Guidelines <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="CodeSystem-ceosys-code-system.html">CEOsys Code System</a>#clinical-practice-guideline; #e07eN1w1Rwswg4)</span></p><p><b>category</b>: Evidence- and consensus-based guideline <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="CodeSystem-cs-guideline-stage-classification.html">Guideline Stage Classification</a>#S3)</span></p><p><b>date</b>: 2022-03-01</p><p><b>author</b>: <a href="Organization-AWMFOrganization.html">Organization/AWMFOrganization</a> &quot;Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e.V.&quot;</p><p><b>title</b>: Empfehlungen zur stationären Therapie von Patienten mit COVID-19 - Living Guideline</p><h3>RelatesTos</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>ResourceReference</b></td></tr><tr><td style="display: none">*</td><td>citation</td><td><a href="Citation-COVID19IntensiveCareTreatmentGuidelineCitation.html">Citation/COVID19IntensiveCareTreatmentGuidelineCitation</a> &quot;COVID19_Intensive_Care_Treatment_Guideline&quot;</td></tr></table></div>
  </text>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="RI"/>
        <display value="Resource identifier"/>
      </coding>
    </type>
    <system value="https://www.awmf.org/"/>
    <value value="113-001"/>
  </identifier>
  <version value="7.0"/>
  <status value="final"/>
  <type>
    <coding>
      <system value="https://www.netzwerk-universitaetsmedizin.de/fhir/screen4care/CodeSystem/ceosys-code-system"/>
      <code value="clinical-practice-guideline"/>
    </coding>
    <coding>
      <system value="https://data.cochrane.org/concepts/"/>
      <code value="e07eN1w1Rwswg4"/>
      <display value="Guidelines"/>
    </coding>
  </type>
  <category>
    <coding>
      <system value="https://www.netzwerk-universitaetsmedizin.de/fhir/screen4care/CodeSystem/cs-guideline-stage-classification"/>
      <code value="S3"/>
      <display value="Evidence- and consensus-based guideline"/>
    </coding>
  </category>
  <date value="2022-03-01"/>
  <author>
    <reference value="Organization/AWMFOrganization"/>
  </author>
  <title value="Empfehlungen zur stationären Therapie von Patienten mit COVID-19 - Living Guideline"/>
  <relatesTo>
    <type value="citation"/>
    <resourceReference>
      <reference value="Citation/COVID19IntensiveCareTreatmentGuidelineCitation"/>
    </resourceReference>
  </relatesTo>
  <section>
    <title value="Stationäre Therapie von COVID-19 Patienten"/>
    <code>
      <coding>
        <system value="https://www.netzwerk-universitaetsmedizin.de/fhir/screen4care/CodeSystem/ceosys-code-system"/>
        <code value="guideline-recommendation"/>
        <display value="Clinical practice guideline recommendation"/>
      </coding>
    </code>
    <focus>
      <reference value="PlanDefinition/COVID19VentilatedPatientsDexamethasoneApplicationPlan"/>
    </focus>
    <text>
      <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><strong>Systemische Steroide:</strong> Bei Patienten mit COVID-19- und Sauerstoff-Bedarf (Niedrigfluss-Sauerstoff-Insufflation, High-Flow Nasal Cannula, Nichtinvasive Beatmung/CPAP, invasive Beatmung) soll eine Therapie mit systemischen Kortikosteroiden erfolgen. Die Therapie sollte mit 6 mg Dexamethason p.o. oder i.v. über zehn Tage erfolgen.</div>
    </text>
  </section>
  <section>
    <title value="Stationäre Therapie von COVID-19 Patienten"/>
    <code>
      <coding>
        <system value="https://www.netzwerk-universitaetsmedizin.de/fhir/screen4care/CodeSystem/ceosys-code-system"/>
        <code value="guideline-recommendation"/>
        <display value="Clinical practice guideline recommendation"/>
      </coding>
    </code>
    <focus>
      <reference value="PlanDefinition/COVID19NonVentilatedPatientsDexamethasoneApplicationPlan"/>
    </focus>
    <text>
      <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><strong>Systemische Steroide:</strong> Bei Patienten mit moderater Erkrankung (hospitalisiert ohne Notwendigkeit von Niedrigfluss-Sauerstoff-Insufflation) soll keine Therapie mit systemischen Kortikosteroiden erfolgen.</div>
    </text>
  </section>
</Composition>